Following a successful cooperation with the DRK-Blutspendedienst NSTOB since 2002, Octapharma leased the DRK's Plasma Fractionation Facility in Springe, Plasmaverarbeitungsgesellschaft mbH (PVG) in April 2006,
Octapharma acquired the PVG in April 2008, which became Octapharma Produktionsgesellschaft Deutschland m.b.H.. At the same time, Octapharma also purchased adjacent farmland with the intention of extending the production facilities and thus ultimately doubling the plant's current annual fractionation capacity and enabling production of most of Octapharma's products. This massive investment project, involving more than €95 million, is ongoing, with the administrative building storage facilities and new QC laboratory already operational. Over 2013, Springe doubled the basic fractionation capacity and employs more than 410 people in 2017.
Environmental and ecological considerations have been a focus in all aspects of the project's design and realisation as the premises borders a nature reserve.
Fractionation / purification; pharmaceutical production; Quality Control laboratories; storage facilities; administrative units
Octapharma Produktionsgesellschaft Deutschland.m.b.H.